Financial Performance - GAAP earnings per share for Q1 2025 was $0.35, up from $0.21 in Q1 2024, representing a 66.7% increase[4] - Revenue for Q1 2025 was $665 million, a 2% increase from $650 million in Q1 2024, with organic growth of 4%[4][7] - Adjusted earnings per share from continuing operations for Q1 2025 was $1.01, compared to $0.98 in the same period last year, reflecting a 3.1% increase[5] - The company reported adjusted operating income of $170 million for Q1 2025, slightly up from $166 million in Q1 2024[5] - Net income for the three months ended March 30, 2025, was $42,237,000, compared to $26,013,000 for the same period in 2024[27] - Adjusted operating profit margin for Q1 2025 was 25.6%, slightly up from 25.5% in the same period last year[5] - Revenue for the three months ended March 30, 2025, was $664,762,000, an increase of 2% compared to $649,920,000 for the same period in 2024[22] - Adjusted operating income for the same period was $169,911,000, representing an operating margin of 25.6%, slightly up from 25.5% in the prior year[22] Revenue Segments - The Life Sciences segment reported Q1 2025 revenue of $324 million, a 3% increase year-over-year, with organic revenue growth of 5%[6] - The Diagnostics segment achieved Q1 2025 revenue of $340 million, a 1% increase from $337 million in Q1 2024, with organic growth of 2%[8] - The Life Sciences segment generated revenue of $340,395,000, while the Diagnostics segment generated $324,367,000 for the three months ended March 30, 2025[22] Guidance and Projections - Full year 2025 revenue guidance has been raised to a range of $2.83-$2.87 billion, with organic growth guidance reaffirmed at 3-5%[10] - The company reaffirmed its adjusted EPS guidance for the full year 2025 at $4.90-$5.00[10] - Projected organic revenue growth for FY 2025 is estimated to be between 3% and 5%[31] Assets and Liabilities - The company reported total assets of $12,360,724,000 as of March 30, 2025, a slight decrease from $12,392,478,000 at the end of 2024[24] - Cash and cash equivalents at the end of the period were $1,138,687,000, down from $1,164,452,000 at the beginning of the period[28] - Total liabilities were reported at $4,723,594,000, with long-term debt amounting to $3,168,384,000[24] Non-GAAP Measures - The company uses "adjusted earnings per share from continuing operations" to exclude various costs, including amortization of intangible assets and acquisition-related expenses, to better reflect ongoing performance[41] - Management believes that amortization of intangible assets does not accurately reflect ongoing operations, as these charges are fixed post-acquisition[42] - Debt extinguishment costs are excluded from non-GAAP measures as they do not reflect the performance of ongoing operations[42] - Significant litigation matters and settlements are not included in adjusted earnings as they do not represent ongoing operational performance[45] - The company excludes asset impairments from non-GAAP measures, believing they do not accurately reflect ongoing operations[45] - Changes in the value of investments are excluded from adjusted earnings, as management believes these do not reflect ongoing operational performance[45] - The impact of foreign currency changes is excluded to avoid obscuring underlying trends in performance[45] - Management uses non-GAAP measures to evaluate operating performance and communicate financial results to the Board of Directors[47] - The company emphasizes that non-GAAP measures should be viewed alongside GAAP financial measures due to their limitations[46] - Non-GAAP measures may differ from similar measures used by other companies, highlighting the need for careful comparison[46] Operational Performance - The company emphasized strong execution and adaptability to macroeconomic changes as key drivers of performance in Q1 2025[6] - Organic revenue growth from continuing operations was 4%, after accounting for a -1% impact from foreign exchange rates[30] - The company incurred $10,586,000 in significant litigation matters and settlements during the quarter[22]

Core Viewpoint - Revvity (RVTY) is positioned to potentially continue its earnings-beat streak in the upcoming report, having surpassed earnings estimates consistently in recent quarters [1][2]. Earnings Performance - For the last reported quarter, Revvity achieved earnings of $1.42 per share, exceeding the Zacks Consensus Estimate of $1.36 per share by 4.41% [2]. - In the previous quarter, the company reported earnings of $1.28 per share against an expected $1.13 per share, resulting in a surprise of 13.27% [2]. Earnings Estimates and Predictions - Recent estimates for Revvity have been trending upward, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5][8]. - The current Earnings ESP for Revvity stands at +0.52%, reflecting increased analyst optimism regarding its near-term earnings potential [8]. Zacks Rank and Success Rate - Revvity holds a Zacks Rank of 3 (Hold), which, when combined with a positive Earnings ESP, suggests a high probability of beating consensus estimates, with historical data indicating nearly 70% success in such scenarios [6][8]. Upcoming Earnings Report - The next earnings report for Revvity is anticipated to be released on April 28, 2025 [8].

Core Viewpoint - Revvity, Inc. (RVTY) is expected to report its first-quarter 2025 results on April 28, with a consensus estimate for revenues at $662.2 million, reflecting a 1.9% increase year-over-year, while earnings per share (EPS) is projected at 96 cents, indicating a 2% decline year-over-year [1][2]. Q1 Estimates - The Zacks Consensus Estimate for revenues is $662.2 million, up 1.9% from the prior-year quarter [1] - The consensus mark for earnings is 96 cents per share, indicating a deterioration of 2% year-over-year [1] - Organic top-line growth is expected to be 3-5% in Q1, with 19% of full-year adjusted EPS guidance of $4.90-$5.00 anticipated in this quarter [2] Diagnostics Segment - The Diagnostics segment sales improved 6% organically in the fourth quarter, with strong performance expected to continue in Q1, driven by growth in Immunodiagnostics and Reproductive Health [3] - Immunodiagnostics is projected to grow in high-single digits, supported by strong commercial execution [3] - The estimated revenue for the Diagnostics segment is $324.8 million, down 6.4% year-over-year [6] Life Sciences Segment - The Life Sciences business improved 5% organically in the last reported quarter, primarily driven by recovery in pharma/biotech customer activity [7] - The estimated revenue for the Life Sciences segment is $338 million, up 11.6% year-over-year [8] - New offerings, Signals Clinical and Signals Synergy, are likely to drive adoption of Signals software during Q1 [7] Other Factors to Consider - Revvity announced an expansion of its work with Genomics England to advance genomic initiatives, which may boost newborn screening [9] - The launch of the TotalSeq Phenocyte single-cell protein profiling solution in collaboration with Scale Biosciences may have contributed additional revenues for the Life Sciences segment [10] - The company generates a portion of its sales from China, which is a crucial growth factor for its business in Asia [11] Earnings Beat Likely - The model predicts an earnings beat for Revvity, with an Earnings ESP of +0.52% [12]

Core Viewpoint - The market anticipates Revvity (RVTY) to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending March 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Revvity is expected to post quarterly earnings of $0.96 per share, reflecting a -2% change year-over-year, while revenues are projected to be $662.71 million, up 2% from the previous year [3]. - The consensus EPS estimate has been revised 0.13% lower in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading indicates a likely earnings beat, particularly when combined with a strong Zacks Rank [8]. - For Revvity, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.52%, but the stock holds a Zacks Rank of 4, complicating predictions of an earnings beat [10][11]. Historical Performance - Revvity has a history of beating consensus EPS estimates, having done so in the last four quarters, including a +4.41% surprise in the most recent quarter [12][13]. Conclusion - While Revvity does not appear to be a strong candidate for an earnings beat, investors should consider other factors influencing stock performance ahead of the earnings release [16].

Revenue and Financial Performance - Revenue for fiscal year 2024 was $2,755.0 million, an increase of $4.5 million, or less than 1%, compared to fiscal year 2023[146]. - Diagnostics segment revenue increased by $42.7 million, or 3%, to $1,500.9 million, driven by growth in immunodiagnostics and reproductive health[157]. - Life Sciences segment revenue decreased by $38.2 million, or 3%, to $1,254.1 million, primarily due to a decline in instruments and reagents revenue[154]. - Total revenue for the year ended December 29, 2024, was $2.755 billion, a slight increase from $2.751 billion in 2023[220]. - Product revenue decreased to $2.338 billion in 2024 from $2.416 billion in 2023, while service revenue increased to $416.8 million from $334.7 million[220]. - Operating income from continuing operations rose to $346.7 million in 2024, compared to $300.6 million in 2023, reflecting a 15.4% increase[220]. - Net income for 2024 was $270.4 million, a significant decrease from $693.1 million in 2023, primarily due to losses from discontinued operations[220]. - Basic earnings per share from continuing operations increased to $2.31 in 2024 from $1.44 in 2023[220]. Expenses and Margins - Consolidated gross margin decreased by 16 basis points to 55.8% in fiscal year 2024, attributed to an unfavorable product mix and higher product costs[147]. - Consolidated operating margin increased by 166 basis points to 16.5% in fiscal year 2024, supported by productivity initiatives and cost containment[144]. - Research and development expenses decreased by $19.7 million, or 9%, to $196.8 million, representing 7.1% of revenue[149]. - Selling, general and administrative expenses decreased by $28.5 million, or 3%, to $994.1 million, accounting for 36.1% of revenue[148]. Cash Flow and Financing Activities - Net cash provided by continuing operations increased to $665.0 million in fiscal year 2024, up from $279.4 million in fiscal year 2023, reflecting higher income and less cash used for working capital[165]. - The company reported net cash used in financing activities of $1,128.2 million for fiscal year 2024, an increase of $181.1 million compared to $947.1 million in fiscal year 2023[168]. - The company authorized a new stock repurchase program for up to $1.0 billion, replacing the previous program, with $857.2 million remaining available for repurchases as of December 29, 2024[175]. - The company received cash proceeds of $2.27 billion from divestitures, with an additional $75 million expected from the Brand Sale and up to $150 million contingent on future sales by the Purchaser[181]. Tax and Interest Expenses - The effective tax rate for fiscal year 2024 was 10.5%, compared to 1.9% in fiscal year 2023[151]. - Interest and other expense, net, decreased significantly from $117.6 million in fiscal year 2023 to $30.6 million in fiscal year 2024[150]. - The total provision for income taxes for continuing operations was $33.1 million in 2024, compared to $3.5 million in 2023[295]. Assets and Liabilities - As of December 29, 2024, the company had cash and cash equivalents of $1,163.4 million, with $1.5 billion of borrowing capacity available under its senior unsecured revolving credit facility[173]. - Total assets decreased to $12.392 billion in 2024 from $13.565 billion in 2023[226]. - Total stockholders' equity decreased to $7.667 billion in 2024 from $7.873 billion in 2023[226]. - The company’s total liabilities decreased from $4,951,018 thousand in 2023 to $5,609,212 thousand in 2024[230]. Goodwill and Intangible Assets - The company's goodwill balance as of December 29, 2024, was $6.5 billion, with $4.3 billion allocated to the Life Sciences reporting unit[214]. - The fair value of the Life Sciences reporting unit exceeded its carrying value by more than 10% but less than 20% as of November 1, 2024[215]. - Total amortization expense related to amortizable intangible assets was $359.4 million in fiscal year 2024, with estimated future amortization expenses projected to decrease over the next five years[317]. Strategic Initiatives and Future Outlook - The company anticipates an increase in capital expenditures in fiscal year 2025, focusing on enhancing digital capabilities and product innovations[172]. - The company plans to fund its strategic initiatives through a combination of existing cash reserves and internally generated funds from continuing operations[172]. - The company expects to recognize substantially all deferred revenue within 12 months of the balance sheet date[287]. Discontinued Operations - For fiscal year 2024, the company recognized a loss of $12.7 million from discontinued operations, compared to income of $513.6 million in fiscal year 2023[162]. - The operating loss from discontinued operations for the fiscal year ended December 29, 2024, was $37.9 million, compared to an operating income of $68.4 million in 2023[292]. Pension and Benefit Obligations - The company recognized a net periodic pension cost of $10,314,000 for fiscal year 2024, compared to $20,062,000 in 2023[329]. - Accumulated benefit obligations for Non-U.S. increased to $212,120, while U.S. obligations rose to $90,293 as of December 29, 2024[332]. - The discount rate for Non-U.S. plans was 4.19% and for U.S. plans was 5.71% as of year-end measurement[332].

Core Viewpoint - Revvity, Inc. reported strong fourth-quarter 2024 results with adjusted EPS of $1.42, exceeding estimates and showing a year-over-year improvement of 13.6% [1][2] Financial Performance - GAAP EPS from continuing operations was 78 cents, up from 64 cents in the prior year, including 5 cents from discontinued operations [2] - Total revenues reached $729.3 million, reflecting a 4.8% year-over-year increase, but slightly missing the Zacks Consensus Estimate by 0.1% [3] Segment Analysis - Life Sciences segment revenues were $336 million, up 5% year-over-year, with adjusted operating income of $131 million, an 11% increase [4] - Diagnostics segment revenues totaled $393 million, a 4.5% year-over-year increase, with organic growth of 6% [4] Margin and Expense Analysis - Selling, general and administrative expenses decreased by 4.8% to $244.3 million, while research and development expenses were $49.2 million, down 0.8% [6] - Adjusted operating income improved by 15.4% to $221.3 million, with an adjusted operating margin of 28.3%, expanding by 280 basis points [6] Cash Flow and Financial Position - The company ended Q4 2024 with cash and cash equivalents of $1.16 billion, down from $1.23 billion in the previous quarter [7] - Net cash provided by operating activities was $174.2 million, compared to a net cash used of $196.6 million in the year-ago quarter [7] 2025 Guidance - For 2025, Revvity expects adjusted EPS in the range of $4.90-$5.00 and revenues between $2.80-$2.85 billion, with Zacks Consensus Estimates at $4.97 and $2.87 billion respectively [8]

Core Insights - Revvity (RVTY) reported revenue of $729.37 million for the quarter ended December 2024, reflecting a year-over-year increase of 4.8% [1] - The company's EPS was $1.42, up from $1.25 in the same quarter last year, surpassing the consensus estimate of $1.36 by 4.41% [1] - The revenue fell slightly short of the Zacks Consensus Estimate of $730.06 million, resulting in a surprise of -0.10% [1] Financial Performance Metrics - Organic revenue growth in Life Sciences was 5%, exceeding the average estimate of 2.7% from three analysts [4] - Total organic revenue growth was reported at 6%, compared to the average estimate of 4.1% [4] - Organic revenue growth in Diagnostics was 6%, surpassing the average estimate of 5.5% [4] Sales Performance - Net Sales in Life Sciences reached $336.34 million, slightly below the average estimate of $344.79 million, but still showing a year-over-year increase of 5.2% [4] - Net Sales in Diagnostics amounted to $393.24 million, exceeding the average estimate of $385.63 million, with a year-over-year growth of 4.5% [4] Stock Performance - Revvity's shares have returned +13.3% over the past month, outperforming the Zacks S&P 500 composite's +2.9% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "e ...

Financial Data and Key Metrics Changes - The company generated total adjusted revenues of $730 million in Q4 2024, resulting in 6% organic growth, which was above expectations [18] - For the full year, total adjusted revenue was $2.76 billion, with 1% organic growth [19] - Adjusted EPS for Q4 was $1.42, exceeding guidance by $0.04, and for the full year, adjusted EPS was $4.90, representing 5% growth year over year [21][22] Business Line Data and Key Metrics Changes - Life Sciences segment generated $336 million in Q4, up 5% on both a reported and organic basis, but down low single digits for the full year [25] - Diagnostics segment generated $393 million in Q4, up 4% on a reported basis and 6% on an organic basis, with 4% organic growth for the full year [27] - The Life Sciences instruments revenue was down high single digits in Q4 and down low double digits for the full year [25] Market Data and Key Metrics Changes - In Q4, organic revenue growth was 5% in Life Sciences and 6% in Diagnostics, with mid single digits growth in the Americas, low single digits in Europe, and mid single digits in Asia, particularly high single digits in China [23] - For the full year, China experienced low single digit growth in diagnostics and mid teens growth in life sciences, but overall, China declined in the low single digits organically [24] Company Strategy and Development Direction - The company plans to step up strategic internal investments in 2025, expecting organic growth to improve [9][31] - A new Life Sciences Solutions business unit will be established, representing approximately 85% of the Life Sciences segment, reflecting a re-segmentation of the Applied Genomics business [14] - The company aims for adjusted operating margin expansion of 20 to 40 basis points in 2025, despite increased investments [31] Management's Comments on Operating Environment and Future Outlook - Management noted that while demand trends have stabilized, the pace of recovery remains uncertain, leading to a cautious outlook for 2025 [39] - The company expects total organic growth in 2025 to be in the range of 3% to 5%, with balanced growth expected throughout the year [30] - Management expressed optimism about the potential for recovery in the Applied Genomics business as it transitions to the Life Sciences Solutions portfolio [63] Other Important Information - The company repurchased $185 million worth of shares in Q4, bringing total buyback activity for 2024 to $370 million [22] - Free cash flow for Q4 was $151 million, with a full year total of $578 million, equating to 96% conversion of adjusted net income [22] Q&A Session Summary Question: Insights on key end markets and recovery areas - Management acknowledged a path to recovery but emphasized uncertainty in the pace of return to normalcy, with diagnostics and software businesses showing signs of improvement while instrumentation remains a concern [39][40] Question: Guidance for China and stimulus impact - Management expects China to align with company growth averages, with modest stimulus impact anticipated [41][42] Question: Segment outlooks relative to overall guidance - Diagnostics is expected to perform above the company average, while Life Sciences is projected to be in the low single digits [46][47] Question: Expectations for reagents growth - Management indicated that the reagents business is gaining market share and is expected to grow in mid single digits for fiscal 2025 [48][50] Question: Q1 guidance and margin visibility - Management noted that Q1 margins are typically below the full year average, with a similar cadence expected as in 2024 [54] Question: Applied Genomics recovery expectations - Management expressed optimism about the recovery of the Applied Genomics business as it transitions to the Life Sciences Solutions portfolio [63] Question: FX impact on margins - Management clarified that FX does not have a material impact on operating margins [66] Question: Strategic investments for 2025 - Management highlighted increased investments in digital capabilities and expanding sales channels as part of their strategy for 2025 [70]

Company Performance - Revvity (RVTY) reported quarterly earnings of $1.42 per share, exceeding the Zacks Consensus Estimate of $1.36 per share, and up from $1.25 per share a year ago, representing an earnings surprise of 4.41% [1] - The company posted revenues of $729.37 million for the quarter ended December 2024, slightly missing the Zacks Consensus Estimate by 0.10%, but up from $695.9 million year-over-year [2] - Over the last four quarters, Revvity has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Market Performance - Revvity shares have increased approximately 13.7% since the beginning of the year, outperforming the S&P 500's gain of 3.2% [3] - The current consensus EPS estimate for the upcoming quarter is $1.11 on revenues of $678.51 million, and for the current fiscal year, it is $4.97 on revenues of $2.87 billion [7] Industry Outlook - The Medical Services industry, to which Revvity belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Revvity's stock may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]